ALDEI.PA Deinove SA EURONEXT pre-market: €0.0265 13.01M shares active
ALDEI.PA stock is trading pre-market on EURONEXT at €0.0265 with 13,014,939 shares reported, making Deinove SA one of the most active small caps in Europe today. Volume is more than double average, at a relative volume of 2.17, pushing the price inside a tight intraday range (€0.0231–€0.0321). Investors are watching biotech catalysts and balance-sheet signals. We use company data, sector context and Meyka AI-powered market analysis to explain why trading activity is elevated and what to watch next.
ALDEI.PA stock: pre-market price action and liquidity
Deinove SA (ALDEI.PA) opened pre-market at €0.0239 and is quoted at €0.0265 with a day high of €0.0321. Volume is 13,014,939 versus an average of 5,992,347, highlighting strong intraday interest. The firm’s market capitalization is €1,134,989, a microcap structure that increases price sensitivity to order flow. Watch spreads and execution costs when trading given low absolute price and high relative volume.
ALDEI.PA stock: fundamentals and valuation snapshot
Deinove operates in Biotechnology within the Healthcare sector listed on EURONEXT in Europe. Latest reported EPS is -0.24 and the trailing P/E is negative. Price-to-sales sits at 3.09 while enterprise value is €3,613,989. Cash per share is €0.1344 and book value per share is -€0.4556, showing negative equity on the books. Current ratio is 1.36, indicating short-term coverage broadly stable but slim for a clinical-stage biotech.
ALDEI.PA stock: operational and clinical drivers
Deinove focuses on microbial-derived compounds and antibiotic candidate DNV3837, currently in Phase II for C. difficile infections. The company also sells cosmetic and nutrition ingredients. Clinical readouts, partner milestones with names like Institut Pasteur or bioM erieux, or manufacturing partnerships could swing sentiment. Given limited revenues per share (€0.0128 TTM), clinical progress is the main value driver.
ALDEI.PA stock: technicals and trading setup
The 50-day average price is €0.02315 and the 200-day average is €0.11427, placing the stock well below long-term trend. Year high is €0.4360 and year low is €0.0062, indicating high historical volatility. Short-term support sits near €0.023, with immediate resistance at €0.032. Relative volume of 2.17 suggests this pre-market move is liquidity-driven rather than steady accumulation.
ALDEI.PA stock: sector context and risk profile
Healthcare and biotech peers have outperformed broader markets in parts of the last year, but sector averages show higher P/Es and stronger margins than Deinove. The Healthcare sector average P/E is around 34.60 while Deinove’s metrics are negative. Key risks include funding needs, clinical trial outcomes and thin free-float liquidity. Opportunities include partnerships and successful Phase II results that could re-rate the stock rapidly.
ALDEI.PA stock: Meyka AI grade and analyst view
Meyka AI rates ALDEI.PA with a score out of 100: Score: 60.82 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The model flags high volatility, negative earnings, but possible upside from clinical catalysts. These grades are not guaranteed and we are not financial advisors. For the company profile see the official site Deinove and detailed metrics on Financial Modeling Prep.
Final Thoughts
Key takeaways for ALDEI.PA stock: volume-led pre-market trading at €0.0265 has placed Deinove among the most active microcaps on EURONEXT. Fundamentals show negative EPS (-0.24) and negative book value per share, so valuation depends on future clinical and commercial milestones. The 50-day average of €0.02315 sits below the current price, while the 200-day average of €0.11427 indicates a longer-term downtrend. Meyka AI’s forecast model projects a baseline target of €0.0600, implying upside of 126.42% from the current €0.0265. A downside stress case to €0.0150 implies a -43.40% move. Forecasts are model-based projections and not guarantees. Traders should manage position size, monitor trial news and partnership updates, and use limit orders given low nominal price and execution risk. For quick reference, see the stock page on Meyka AI for live updates and signals ALDEI.PA on Meyka.
FAQs
What is driving the pre-market activity in ALDEI.PA stock?
Pre-market activity stems from heavy trading volume of 13,014,939 shares and news sensitivity in biotech. Clinical trial milestones, partner updates or liquidity shifts often trigger large moves in a microcap like Deinove.
How does Deinove’s balance sheet affect ALDEI.PA stock valuation?
Deinove reports €0.1344 cash per share and negative book value (-€0.4556). Limited revenues and negative EPS mean valuation is forward-looking and tied to clinical success and partnerships rather than current profits.
What price target does Meyka AI give for ALDEI.PA stock?
Meyka AI’s forecast model projects a baseline target of €0.0600, implying +126.42% from €0.0265. This is a model projection and not a guarantee; outcomes depend on trials and funding.
Is ALDEI.PA stock a buy for short-term traders?
Short-term trades may profit from high intraday volume, but risk is high due to microcap volatility and thin liquidity. Use tight risk controls, small size, and limit orders when trading ALDEI.PA stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
